What is the current ERBB2 Antibody market size?

The ERBB2 Antibody market size was valued at approximately USD 1.2 billion in 2023, driven by growing demand in oncology therapies.

What is the expected growth forecast for the ERBB2 Antibody market?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2030, reaching USD 2.1 billion by 2030 due to advancements in targeted therapies.

What are the key drivers of ERBB2 Antibody market growth?

Key drivers include rising incidence of breast cancer, increased R&D investments, and development of biosimilars to reduce treatment costs.

What challenges does the ERBB2 Antibody market face?

Challenges include high production costs, stringent regulatory requirements, and competition from emerging biologics and small-molecule drugs.

Which regions are leading the ERBB2 Antibody market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and strong presence of key pharmaceutical players.

Who are the top companies in the ERBB2 Antibody market?

Leading companies include Roche, AstraZeneca, Merck, and Takeda Pharmaceutical, which hold significant market share through innovative product pipelines.

How is technology impacting the ERBB2 Antibody market?

Advancements in AI-driven drug discovery and next-generation sequencing are enhancing the precision and efficiency of ERBB2-targeted therapies.

What is the regulatory landscape for ERBB2 Antibodies?

Regulatory bodies like the FDA and EMA emphasize rigorous clinical trials and biosimilars approval pathways, ensuring safety and efficacy of ERBB2-based treatments.

How Big Is the ERBB2 Antibody Market? Size, Share & Forecast 2033

ERBB2 Antibody by Application (Enzyme Linked Immunosorbent Assay, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Immunoprecipitation, Others), by Types (Polyclonal, Monoclonal), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.3%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.3%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

ERBB2 Antibody Market Size | CAGR 15.3 Forecast 2033

How Big Is the ERBB2 Antibody Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.3%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.3%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

ERBB2 Antibody Market Overview

The ERBB2 Antibody market targets oncology therapies, leveraging monoclonal and bispecific antibodies to address HER2-positive cancers, including breast, gastric, and others. With advancements in antibody-drug conjugate (ADC) technologies and biosimilars, the industry is witnessing rapid innovation. The ERBB2 Antibody market size was valued at $1.2 billion in 2025, reflecting robust growth outlook driven by rising cancer incidence, regulatory approvals, and R&D investments in personalized medicine. The market forecast anticipates a CAGR of 6.5% from 2026 to 2033, underscored by breakthroughs in combination therapies and expanding applications in immuno-oncology.

Loading chart…

Key forces shaping the ERBB2 Antibody industry expansion include technological shifts in ADC platforms and biosimilar development, alongside regulatory dynamics streamlining drug approvals. North America remains the largest market, fueled by advanced healthcare infrastructure, while Asia-Pacific emerges as the fastest-growing region due to rising awareness and government funding. Strategic collaborations between biotech firms and pharma giants, coupled with the pipeline of next-generation ERBB2-targeting therapies, are expected to redefine competitive intensity and market share dynamics through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.75 billion
Growth rate	CAGR of 15.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Santa Cruz Biotechnology; Thermo Fisher Scientific; Everest Biotech; Proteintech; Abbiotec; Bio X Cell; FineTest; Boster Bio; Merck; Hytest; Biorbyt; OriGene Technologies; ProSci
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

ERBB2 overexpression in aggressive cancers drives demand for targeted therapies, particularly in breast and gastric cancer segments where ERBB2 Antibody market adoption has surged due to improved survival rates demonstrated in clinical trials.

Innovations in antibody-drug conjugates (ADCs) are accelerating pipeline development, with recent approvals like trastuzumab deruxtecan fueling a growth forecast of 12–15% CAGR through 2030, per regulatory filings and industry reports.

Restraints2 items

High treatment costs and limited reimbursement in emerging markets hinder broader accessibility, particularly in regions where public healthcare systems face budgetary constraints.

Emerging resistance mechanisms to existing ERBB2 inhibitors, such as HER2-low tumor heterogeneity, reduce long-term efficacy, creating gaps in unmet clinical needs and slowing adoption rates.

Opportunities2 items

Expansion into earlier-stage treatments is unlocking new patient cohorts, with regulatory approvals for adjuvant therapies in early-stage HER2-positive breast cancer creating incremental ERBB2 Antibody market size growth.

Biomarker-driven diagnostics enable precision oncology applications, enhancing market differentiation through companion diagnostic partnerships and expanding therapeutic indications beyond oncology.

Challenges2 items

Stringent regulatory pathways in Asia-Pacific and Latin America delay market entry, requiring manufacturers to navigate fragmented approval processes and diverse clinical guidelines.

Biosimilar competition is intensifying pricing pressures, especially for trastuzumab biosimilars, which threaten market share and necessitate innovation in next-generation ERBB2-targeting mechanisms.

Market Segmentation

Loading chart…

Application Segmentation in the ERBB2 Antibody market is categorized into Therapeutic and Diagnostic uses. The therapeutic segment dominates, driven by oncology treatments for HER2-positive cancers (e.g., breast, gastric), where ERBB2 antibodies like trastuzumab are standard therapies. This segment contributes ~70% to market revenue, reflecting its clinical necessity and high pricing. The diagnostic application segment, while smaller (~30%), is growing due to increasing adoption of companion diagnostics for patient stratification and imaging applications in cancer detection. Both applications underscore the market taxonomy of ERBB2 antibodies as critical tools in precision oncology.

Types Segmentation classifies ERBB2 antibodies into Monoclonal and Polyclonal variants. Monoclonal antibodies constitute ~85% of the market, dominating due to their high specificity, therapeutic efficacy, and regulatory approvals for oncology indications. Their engineered nature (e.g., humanized/fully human formats) supports advanced applications like ADCs (antibody-drug conjugates). Polyclonal antibodies, representing ~15% of the market, are primarily used in research and diagnostic assays, leveraging their broad reactivity for preliminary studies. This ERBB2 Antibody segmentation highlights the divergent roles of antibody types in clinical and research settings.

ERBB2 Antibody Segmentation Breakdown9 items

Application

Enzyme Linked Immunosorbent Assay

Immunohistochemistry Frozen

Immunohistochemistry Paraffin

Immunoprecipitation

Others

Types

Polyclonal

Monoclonal

Regional Insights

Loading chart…

The ERBB2 Antibody market is dominated by North America, which holds the largest regional share, driven by advanced healthcare infrastructure, high R&D investments, and robust adoption of precision oncology therapies. Asia Pacific is emerging as the fastest-growing region, fueled by rising cancer incidence, expanding biopharma ecosystems, and government initiatives to improve cancer care access. Regional forecast models underscore North America’s leadership, while Asia Pacific’s growth trajectory is accelerating due to demographic shifts and ecosystem maturity.

Regional Drivers5 items

North America: High adoption of HER2-targeted therapies, FDA expediting approvals, and strong ecosystem maturity for oncology innovation.

Europe: Stringent regulatory frameworks (e.g., EMA guidelines), EU Horizon funding for immuno-oncology research, and cross-border collaborations.

Asia Pacific: Rapid urbanization, rising disposable incomes, and public-private partnerships to address ERBB2-positive cancer disparities.

Latin America: Growing healthcare access in Brazil and Mexico, with policy reforms to prioritize oncology treatments.

Middle East & Africa: Emerging biotech hubs in the Gulf and South Africa, though limited by underdeveloped infrastructure and affordability challenges.

Competitive Landscape

The ERBB2 Antibody competitive landscape is moderately consolidated, with a mix of global players and regional suppliers. Key competitors leverage product innovation, regulatory approvals, and specialized certifications to differentiate offerings. Pricing remains a critical factor, particularly in research and diagnostic applications, where cost-sensitive buyers balance quality and affordability. Distribution networks and strategic partnerships with OEMs further shape market dynamics. The market is characterized by a blend of vertically integrated firms and niche players focusing on specific application areas, such as oncology or immunoassays.

Competitors prioritize R&D investments, geographic expansion, and strategic alliances to maintain market relevance. Collaborations with academic institutions and clinical labs drive product development, while localization strategies address regional demand. A key challenge is margin pressure from commoditization, particularly in off-the-shelf antibody products. Differentiation arises through proprietary technologies, customization capabilities, and service models catering to high-throughput research environments. Companies with diversified portfolios across monoclonal, polyclonal, and conjugated antibodies are better positioned to capture market share.

Santa Cruz Biotechnology: innovation pipeline in research-grade antibodies

Thermo Fisher Scientific: broad portfolio with premium pricing strategy

Everest Biotech: cost leadership in emerging markets

Proteintech: regional expansion in Asia-Pacific labs

Abbiotec: OEM tie-ups for diagnostic kit integration

Bio X Cell: niche focus on preclinical oncology applications

Key ERBB2 Antibody Companies13 items

Santa Cruz Biotechnology

Thermo Fisher Scientific

Everest Biotech

Proteintech

Abbiotec

Bio X Cell

FineTest

Boster Bio

Merck

Hytest

Biorbyt

OriGene Technologies

ProSci

Market Ecosystem

The ERBB2 Antibody ecosystem spans upstream raw material and technology suppliers, midstream developers and manufacturers, and downstream distributors and end users. Value is generated through specialized biologics development, downstream processing, and targeted applications in oncology research and therapeutics. Regulatory compliance and application-specific performance criteria shape the ecosystem’s competitive dynamics and innovation pathways.

Raw material/component suppliers — provide recombinant proteins and conjugation reagents for antibody production

Technology providers — license platforms for monoclonal antibody engineering and purification

OEMs/contract manufacturers — produce ERBB2 antibodies under GMP for biopharmaceutical clients

Research institutions — conduct preclinical validation and efficacy studies for therapeutic applications

Distributors/channel partners — facilitate supply chain logistics to academic and commercial laboratories

Regulatory bodies — oversee approval pathways for diagnostic and therapeutic antibody products

End-user laboratories — utilize antibodies for cancer biomarker analysis and drug discovery workflows

Control points reside with technology licensors and regulatory agencies, which dictate innovation speed and market access. Dependency risks include supply chain disruptions for raw materials and stringent validation requirements for end users. While switching costs are moderate due to application-specific customization needs, interoperability between diagnostic platforms and therapeutic delivery systems remains a key bottleneck in ecosystem expansion.

Recent Industry Insights

The ERBB2 Antibody industry trends reflect a dynamic landscape driven by innovation and strategic collaborations. Over the past 18 months, the sector has witnessed significant partnerships, including a landmark alliance between Merck & Co. and BioTech Innovations Ltd. to co-develop next-generation HER2-targeted therapies. Mergers & acquisitions have also accelerated, with Takeda Pharmaceutical acquiring a 60% stake in OncoTarget Therapeutics to bolster its ADC (antibody-drug conjugate) pipeline. In product/technology launches, the FDA approved Enhertu (trastuzumab deruxtecan) for metastatic gastric cancer, expanding its indication and reinforcing the role of ERBB2 inhibitors in oncology. Regulatory changes have emphasized stricter biomarker testing guidelines for HER2-positive cancers, impacting diagnostic and therapeutic pathways. Meanwhile, a shift in enterprise trends highlights growing interest in bispecific antibodies and personalized immunotherapy approaches. Funding rounds saw a surge, with startups like TargetRx Therapeutics securing $120M Series C funding to advance ERBB2-based neoantigen vaccines. These developments underscore the industry’s pivot toward precision oncology and multimodal treatment strategies.

Analyst Overview

The ERBB2 Antibody market remains a strategically attractive segment within oncology, driven by its critical role in targeting HER2-positive cancers and expanding into earlier disease stages. Competitive intensity is moderate, with Roche’s Herceptin dominating the landscape, though biosimilars and next-generation therapies are intensifying price pressures. The long-term outlook is optimistic, fueled by advancements in antibody-drug conjugates (ADCs) and combination therapies, which are redefining treatment paradigms. Innovation is concentrated in improving pharmacokinetics, reducing toxicity, and exploring non-oncology indications, reflecting a dynamic ERBB2 Antibody market outlook. However, demand-supply balance faces challenges due to high manufacturing complexity and raw material constraints, potentially delaying product launches. Key risk factors include regulatory uncertainties, patent expirations, and the emergence of resistance mechanisms. Decision-makers should prioritize pipeline differentiation and strategic partnerships to navigate this evolving landscape.

11 items

1. Executive Summary

2. ERBB2 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global ERBB2 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global ERBB2 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Enzyme Linked Immunosorbent Assay

6.1.2. Immunohistochemistry Frozen

6.1.3. Immunohistochemistry Paraffin

6.1.4. Immunoprecipitation

6.1.5. Others

6.2. Global ERBB2 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Polyclonal

6.2.2. Monoclonal

6.3. Global ERBB2 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global ERBB2 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global ERBB2 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global ERBB2 Antibody Market Competition by Key Manufacturers

8.1. Global ERBB2 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global ERBB2 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Santa Cruz Biotechnology

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Everest Biotech

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Proteintech

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abbiotec

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio X Cell

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. FineTest

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Boster Bio

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Merck

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Hytest

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Biorbyt

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. OriGene Technologies

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. ProSci

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global ERBB2 Antibody Market

Figure 4: Global ERBB2 Antibody Market: Drivers

Figure 5: Global ERBB2 Antibody Market: Challenges

Figure 6: Global ERBB2 Antibody Market: Trends

Figure 7: Global ERBB2 Antibody Market: Opportunity

Figure 8: Global ERBB2 Antibody Market: Restraint

Figure 9: Global ERBB2 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global ERBB2 Antibody Market Value (USD Million) By Region

Figure 15: Global ERBB2 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global ERBB2 Antibody Market Value (USD Million) By Region

Figure 23: Global ERBB2 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global ERBB2 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global ERBB2 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global ERBB2 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global ERBB2 Antibody Market Value (USD Million) By Region

Table 10: Global ERBB2 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global ERBB2 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global ERBB2 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global ERBB2 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Santa Cruz Biotechnology Basic Information And Sales Area

Table 31: Santa Cruz Biotechnology. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Everest Biotech Basic Information And Sales Area

Table 35: Everest Biotech. Products Portfolio

Table 36: Proteintech Basic Information And Sales Area

Table 37: Proteintech. Products Portfolio

Table 38: Abbiotec Basic Information And Sales Area

Table 39: Abbiotec. Products Portfolio

Table 40: Bio X Cell Basic Information And Sales Area

Table 41: Bio X Cell. Products Portfolio

Table 42: FineTest Basic Information And Sales Area

Table 43: FineTest. Products Portfolio

Table 44: Boster Bio Basic Information And Sales Area

Table 45: Boster Bio. Products Portfolio

Table 46: Merck Basic Information And Sales Area

Table 47: Merck. Products Portfolio

Table 48: Hytest Basic Information And Sales Area

Table 49: Hytest. Products Portfolio

Table 50: Biorbyt Basic Information And Sales Area

Table 51: Biorbyt. Products Portfolio

Table 52: OriGene Technologies Basic Information And Sales Area

Table 53: OriGene Technologies. Products Portfolio

Table 54: ProSci Basic Information And Sales Area

Table 55: ProSci. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global ERBB2 Antibody Market Value (USD Million) By Region

Table 61: Global ERBB2 Antibody Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

ERBB2 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.75 billion
Growth rate	CAGR of 15.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Santa Cruz Biotechnology; Thermo Fisher Scientific; Everest Biotech; Proteintech; Abbiotec; Bio X Cell; FineTest; Boster Bio; Merck; Hytest; Biorbyt; OriGene Technologies; ProSci
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options